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Introduction 
Nanoparticles play a very important role in cancer research. Due to extremely 
small size of Nanoparticles they are easily and more readily taken up by the human 
body. Biological membranes and access cells, tissues and organs are eligible for 
entrance of Nanoparticles. Nanoparticles  are stable, solid colloidal particles consist of 
biodegradable polymer or lipids and size range 10-1000 nm. Nanoparticles have 
attracted the attention of scientists because of their multifunctional character. 
Nanoparticles have greater surface area to volume ratio, that helps in the diffusion 
process. Nanoparticles also leading to special properties such as increased heat and 
chemical resistance. A single cancerous cell, giving a strain on the nutrient supply and 
removal of metabolic waste products. If small tumor has formed, the normal tissue 
will not be able to oppose the cancer cells for the normal supply of nutrients from the 
blood.1 
The advantages of Nanoparticles as drug delivery systems include time 
controlled drug delivery, reduced drug toxicity, improved bioavailability and 
enhanced therapeutic efficacy and biodistribution.2 Nanoparticles can also protect the 
sensitive drugs from degradation by environmental factors such as stomach acid and 
enzymes.3 PolymericNanoparticles range in size from about 10-1000 nm, and can be 
modified with different ligands such as antibodies to create a smart targeting delivery 
system.4 Polymeric Nanoparticles of a size around or less than 300 nm coated with 
surfactants have been proved to be able to transport drugs across the Blood Brain 
Barrier BBB. 5 
Nano-Capsules are systems in which the drug is confined to a cavity 
surrounded by a unique polymer membrane . 
Nanoarticles are matrix systems in which the drug is physically  and uniformly 
dispersed.(Fig 1).   
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a                                                          b   
Fig.1: Schematic Representation of Nanoparticles in matrix system 
(a) , Nanocapsules in polymer membrane system (b) 
 
In recent years, biodegradable Polymeric Nanoparticles, particularly those coated with 
hydrophilic polymer such as Poly(ethylene Glycol) (PEG) known as long-circulating 
particles, have been used as potential drug delivery devices because of their ability to 
circulate for a prolonged period time target a particular organ, as carriers of DNA in 
gene therapy, and their ability to deliver (Fig 2). 
 
 
Fig.2: Nanoparticle Drug Delivery System 
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1.1 Etiology of Cancer  
The colon is the part of the digestive system where the waste material is 
stored. The rectum is the end of the colon adjacent to the anus. Together, they form a 
long, muscular tube called the large intestine (also known as the large bowel). Tumors 
of the colon and rectum are growths arising from the inner wall of the large intestine. 
Benign tumors of the large intestine are called polyps (Fig 3). Malignant tumors of 
the large intestine are called Cancers. Benign polyps do not invade nearby tissue or 
spread to other parts of the body. Benign polyps can be easily removed during 
colonoscopy and are not life-threatening. If benign polyps are not removed from the 
large intestine, they can become malignant (cancerous) over time. Most of the cancers 
of the large intestine are believed to have developed from polyps. Cancer of the colon 
and rectum (also referred to as colorectal cancer) can invade and damage adjacent 
tissues and organs. Cancer cells can also break away and spread to other parts of the 
body (such as liver and lung) where new tumors form. The spread of colon cancer to 
distant organs is called metastasis of the colon cancer (Fig 4) and (Fig 5) Once 
metastasis has occurred in colorectal cancer, a complete cure of the cancer is unlikely. 
Globally, cancer of the colon and rectum is the third leading cause of cancer in 
males and the fourth leading cause of cancer in females 
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Fig.3:Diagrammatic representation of colon cancer 
 
 
Fig.4: Micrograph of a tubular adenoma (left of image), a type of colonic           
           polyps anda precursor of colorectal cancer. 
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Fig.5: Endoscopic image of colon cancer identified in sigmoid colon on screening. 
 Cancer therapy strategies are currently focussed on surgery, chemotherapy, 
radiotherapy, immunotherapy and hormonal therapy. These conventional strategies 
are limited by the accessibility to the tumor and the lack of selectivity towards tumor 
cells, the spread of cancer cells throughout the body, and the risk of operating on a 
vital organ. Regarding cancer chemotherapy, treatment failure is frequently 
encountered even in the most sensitive cancers to chemotherapy agents.6 Several 
reasons have been pointed out for chemotherapy failure: i) the Physicochemical 
properties of many drugs, e.g., hydrophobicity, promotes the unsuccessful localization 
at the cancer site ii) Unfavorable pharmacokinetics (rapid clearance and rapid in vivo 
degradation) determine the need of higher doses and rigorous treatment schedules to 
obtain a therapeutic effect iii) The relative poor selectivity of chemotherapy agents for 
targeted tumor cells iv) the large biodistribution and non-intended extravasation with 
severe side effects in non-targeted sites; and v) The susceptibility to induce drug 
resistance .7, 8, 9. 
 Cancer physiology is also responsible for the chemotherapy failure, mainly 
because of the absence of a non-functional lymphatic system that allows drug 
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escaping out of the tumor, and due to a very high hydrostatic pressure gradient inside 
the tumor that difficult a uniform drug diffusion inside the tumor.10,11 The association 
of anti-tumor drugs to colloidal delivery systems in cancer treatment has been 
proposed to improve their efficacy and to reduce their associated toxicity. This 
strategy could allow obtaining a specific accumulation at the tumor site, an 
improvement of the pharmacokinetic profile, a prolongation of the exposure of the 
tumor cells to these active agents and a minimization of the severe side effects.7,12 
 With this, it have been established that a suitable anti-tumor drug delivery 
system should have the following properties: i) small size (≤ 500 nm) to allow a large 
biodistribution and an adequate perfusion at the target site ii) the ability to deliver 
therapeutic drug quantities, without overloading the organism with foreign material; 
iii) physical stability and low drug leakage problems under storage and in vivo  iv) 
controlled drug release rates exclusively at the targeted tumor; and v) maximum 
biocompatibility and biodegradability (with very low toxicity of breakdown products), 
and minimal antigenicity.7,13 These drug carriers are frequently based on vesicular 
(liposomes and niosomes) and polymeric systems. Special approaches such as 
surface-functionalization (e.g., with specific ligands to tumor cells) and engineering 
of stimuli-sensitive materials, could enhance the biodistribution profile of loaded 
drugs and, thus, resulted in a more efficient tumor therapy.7,11,14 
One of the most promising materials for the design of nanocarriers loaded with 
chemotherapy agents is the biodegradable polymer poly(ε-Caprolactone) (PCL). This 
aliphatic polyester is very suitable for controlled drug delivery due to its high 
permeability to many drugs and non-toxicity, its exceptional ability to form blends 
with other polymers, and its very low degradation rate (compared to other well known 
drug carriers, such as Poly(D,Lactide-co-glycolide) (PLGA).15 
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Table 1:Types of Nanoparticles applied in Drug Delivery  
Release System 
S.No Type of 
Nanoparticle 
Materials Used Application 
1  Nanosuspensions 
and Nanocrystals  
Drug powder is 
dispersed in surfactant 
solution  
Stable system for 
controlling delivery of 
poorly soluble drug  
2  Solid lipid 
Nanoparticles  
Melted lipid dispersed 
in  
Aqueous surfactant  
Least toxic and more 
stable Colloidal carrier 
systems as alternative 
materials For polymers  
3  Polymeric 
Nanoparticles  
Biodegradable 
polymers  
Controlled and targeted  
Drug delivery  
4  Polymeric micelles  Amphiphilic block Co 
polymers  
Controlled and systemic  
Delivery of water 
insoluble Drugs  
5  Magnetic 
Nanoparticles  
Magnetite Fe2O3, 
Meghe Mite coated 
with dextran  
Drug targeting 
diagnostics to in medicine  
6  Carbon Nanotubes  Metals, semiconductors 
or carbon 
Gene and DNA delivery  
Controlled release of 
drugs 
7 Liposomes  Phoshpolipid vesicles  Controlled targeted drug  
Delivery  
8  Nanoshells  Dielectric core and 
metal shell  
Tumor targeting  
9  Ceramic 
Nanoparticles  
Silica, alumina, Titania  Drug and biomolecule  
Delivery  
10  Nanopores  Aerogel, which is 
produced by cell gel 
chemistry  
Controlled release drug  
Carriers  
11  Nano wires  Silicon, cobalt, gold or  
Copper based 
nanowires  
Electron transport in nano 
Electronics  
12  Quantum dots  CD Se-CDs core shell  Targeting, imaging agent  
13  Nano films  Polypeptides  Systemic or local drug  
Delivery.  
14  Ferrofluids  Iron oxide magnetic  
Nanoparticles 
surrounded by 
polymeric layer.  
For capturing cells and 
other biological targets.  
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1.2.1 Nanosuspension 
A suspension of drug Nanoparticles in a liquid is called as Nanosuspension. A 
size of the Nanoparticle lies in between 200 to 500 nm. and exceptional feature of 
nanosuspension is the increased saturation, solubility, the increased dissolution rate of  
compound.16 The saturation and solubility increase below a particle size of 1 
mm. An additional characteristic of nanosuspension is that they may induce changes 
in the crystalline structure increases the amorphous portion in particle or even creating 
completely amorphous particles. Nanoparticles and Nanosuspensions show an 
increased adhesiveness to tissue. The oral administration of drugs in the form of 
Nanosuspension  
Examples of Nanosuspension: Nanosuspension of Ibuprofen is prepared by 
emulsion-solvent diffusion technique for the purpose of improving ocular availability, 
whereas nanosuspension of Danazole is formulated by nanocrystal technology to 
improve bioavailability.17 
1.2.2 Solid Lipid Nanoparticles (SLN) 
The solid lipid Nanoparticles are sub micron colloidal carriers (50-1,000nm) 
which are composed of physiological lipid, dispersed in water or in aqueous 
surfactant solution. In order to overcome the disadvantages associated with liquid 
state of oil droplets, liquid lipid replaced by a solid lipid, which eventually 
transformed into solid lipid Nanoparticles.18 
1.2.3 Polymeric Nanoparticles 
The drug is dissolved, entrapped, absorbed, attached or encapsulated into 
Nanoparticle matrix. Depending on the process of preparation, Nanoparticles, 
Nanospheres or Nanocapsules can be obtained with different properties and release 
characteristics for an encapsulated therapeutic agent.Nanoparticles are vesicular 
systems in which the drug is restricted to a cavity surrounded by unique polymer 
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membranes, whereas nanospheres are matrix systems in which the drug is physically 
and uniformly dispersed. The advantages of using Nanoparticles for drug delivery 
result of their two main basic properties. First, Nanoparticles, because of their small 
size, can penetrate through smaller capillaries and are taken up by cells, which allow 
efficient drug accumulation at the target sites. Second, the use of biodegradable 
materials for Nanoparticle preparation allows sustained drug release within the target 
site over a period of days or even weeks.19 
1.2.4 Polymeric Micelles 
Polymeric micelles have been extensively studied as drug carriers. Polymeric 
micelles have enhanced thermodynamic stability in physiological solution, as 
indicated by their low critical micellar concentration, which makes polymeric 
micelles stable and avoid their rapid dissociation in vivo. 
Micelles have a fairly narrow size distribution in the nanometer range and are 
characterized by their exclusive core-shell architecture, in which hydrophobic 
segments are segregated from the aqueous exterior. 
Micellar systems are useful for the systemic delivery of water-insoluble drugs. 
Drugs can be partitioned in the hydrophobic cores of micelles and the outer 
hydrophilic layer from steady dispersion in aqueous media which can then be 
administered intravenously. The distribution of drug-loaded polymeric micelles (less 
than 100 nm in diameter), following intravenous administration, polymeric micelles 
have been shown to have extended systemic circulation time because of their smaller 
size and hydrophilic shell, which minimizes their uptakes by the reticuloendothelial 
System. Polymeric micelle-incorporated drugs may accumulate to a greater extent 
than free drugs into tumors and exhibit reduced distribution in nontargeted areas.20,21 
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1.2.5 Magnetic Nanoparticles 
Magnetic Nanoparticles are influential and adaptable diagnostic device in the 
field of medicine. Magnetic immunoassay techniques have been developed in which 
the main ground generated by the magnetically labeled target detected directly with 
sensitive magnetometer. Superparamagnetic Nanoparticles are used as contrast agents 
in magnetic resonance imaging .The magnetic Nanoparticle are coated with inorganic 
core of iron oxide with polymer such as Dextran. Magnetic Nanoparticles of 
Indomethacin demonstrated selective targeting under magnetic field of 8000 OE-
strength, following normal administration, the drug concentration was higher in the 
Liver and Spleen where endocytosis and phagocytosis could occur.22 
1.2.6 Carbon Nanotubes 
Carbon Nanotubes are a new form of carbon molecule around in a hexagonal 
complex of carbon atoms, these hollow cylinders can have diameter as a small as 
0.7nm and reach several millimeters in length. Each end can be opened or closed by a 
fallen half molecule. The small dimensions of Nanotubes, combined with their 
remarkable physical, mechanical and electrical properties, make them unique 
materials. The mechanical strength of carbon Nanotubes is more than sixty times 
greater than that of the best steel, even though they weigh six times less. They also 
represent a very large specific surface area, are outstanding heat conductors and 
display unique electronic properties, offering three dimensional configurations. They 
have higher capability for molecular absorption.23 
1.2.7 Liposomes 
Liposomes have been used as a versatile tool in biology, biochemistry and 
medicine. Liposomes are small synthetic vesicles of spherical shape that can be 
produced from natural, non toxic Phospholipids and Cholesterol. Because of their 
size, hydrophilic and hydrophobic character, as well as biocompatibility, liposomes is 
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promising system for drug delivery. Properties of Liposomes are different 
substantially with lipid composition, size, surface charge and the method of 
preparation. They are therefore classified into three classes based on their size and 
number of bilayers. Small unilamellar vesicles (SUV) are surrounded by a single lipid 
layer and are 25-50nm in diameter. Large Unilamellar Vesicles (LUV) are a 
heterogeneous group of vesicles similar to SUVs and are surrounded by a single lipid 
layer. Multilamellar vesicles (MLV) consist of several lipids separated from one 
another by a layer of aqueous solution.Drugs associated with liposomes have 
markedly altered pharmacokinetics properties compared to drugs in solution. They are 
also effective in reducing systemic toxicity and preventing early degradation of the 
encapsulated drug after introduction to the target organism.24 
1.2.8 Nanoshells coated with Gold 
Gold nanoshells are new composite Nanoparticles that combine infrared 
optical activity with the uniquely biocompatible properties of gold colloid. Metal 
nanoshells are concentric spherical Nanoparticles consisting of a dielectric (typically 
Gold sulfide or silica) core and a metal (Gold) shell. By varying the relative thickness 
of the core and shell layers, the plasmon-derived optical resonance of gold can be 
considerably shifted in wavelength from the visible region of highest physiological 
transmissivity. By varying the absolute size of the gold nanoshell, it can be made to 
either selectively absorb (for particle diameter < 75nm) or scatter incident light. 
Because the gold shell layer is deposited using the same chemical method used to 
grow gold colloid, the surface properties of gold nanoshells are nearly identical to 
those of gold colloid. Gold Nanoshells can be used to breast cancer cells.25 
1.2.9 Ceramic Nanoparticles 
The newly rising area of using inorganic (ceramic) particles with entrapped 
biomolecule has possible applications in many frontiers of modern materials science 
including drug delivery system. The advantages of ceramic Nanoparticles include 
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easy preparation with the desired size, shape and porosity, and no effect on swelling 
or porosity with no change in the.26 
1.2.10  Nanopores 
Materials with defined pore-sizes in the nanometer range are of special interest 
to a broad range of industrial application because of their wonderful properties with 
regard to thermal insulation, controllable material separation and release and their 
applicability as templates or fillers for chemistry and catalysis. One example of 
nonporous material is aerogel, which is produced by soil-gel chemistry.26 
1.2.11 Nanowires 
Nanowires are conductive or semi conductive particles with a crystalline 
structure of a few dozen nm and a high length /diameter ratio. Silicon, Cobalt, Gold or 
Copper-based nanowires have already been produced. They are used to transport 
electrons in nanoelectronics they could be composed of different metals, Oxides, 
Sulfides and Nitrites.27 
1.3  Benefits of Nanoparticles drug delivery system  
 Nanoparticles can easily pass through the smallest capillary vessels due 
to their ultra tiny volume. 
 They can avoid the rapid clearance by phagocytes so that the duration in 
the bloodstream can be prolonged. 
 Nanoparticles can easily penetrate the cells and tissue gap to arrive at 
target organs eg. Liver, Spleen, Sungs, spinal cord, and Lymph’s. 
 It shows the controlled release property. 
 Site specific targeting by attaching the ligands to the surface of the 
spheres. 
 They can be easily administered by various routes including oral, nasal, 
parenteral, etc. 
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 Reduction of toxicity is also an important advantage of Nanospheres. 
1.4 Drawback of Nanoparticles drug delivery system 
 The physical handling of Nanospheres is difficult in liquids and in dry 
form. 
Due to the smaller size and larger surface area of Nanospheres, chances 
of particle aggregation increases. 
 Drug loading and burst release are limited due to the smaller size and 
larger surface area.28 
1.5  Nanoparticles as targeted drug delivery   
There are various ways of using of Nanoparticles as targeted drug delivery                                  
system. 
1.5.1 Targeting of the tumor 
Basically Nanoparticles are able to distribute the concentrate dose of the drug 
to the tumor targets through permeability enhancing and retention effect or active 
targeting by ligands on the surface of Nanoparticles. It Is can decrease the toxicity by 
reducing the drug disclosure of health tissue by limiting drug distribution to the target 
organ. Nanoparticles have a higher concentration manifested in Liver, Spleen, Lungs 
than in other parts of the body.By this study we can say that there is no doubt that 
Nanoparticles have an effective role in the treatment of cancer. But they have a 
drawback which was reported that during distribution of drug which is incorporated 
into the Nanoparticles mainly accumulated in the liver. 56% of drug accumulated in 
the liver and only 1.6% of drug reaches the tumor. Thus we can say that Nanoparticles 
have a greater tendency to be captured by the liver. So it is a great challenge to avoid 
particle uptake by the Mononuclear Phagocyte System (MPS) in spleen and liver for 
using Nanoparticles for tumor targeting. It has been proved that using doxorubicin 
with Nanoparticles have a great effect against hepatic metastasis than free drug used. 
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1.5.2 Long circulation of Nanoparticles 
Basically Nanoarticles are able to target tumors, which are localized outside 
MPS For long circulation of Nanoparticles a major break came in the field when 
hydrophilic polymer (PEG, Poloxamine) is coated on the surface of Nanoparticles by 
which reverse effect is produced to the uptake by the MPS. 
The coating provides a cloud of hydrophilic and neutral chain at the particle 
surface which repels plasma proteins. As a result coated Nanoparticles become 
imperceptible to MPS and remain for a longer duration during circulation. 
1.5.3 Nanoparticles for oral delivery 
It is very hard to use the bioactive molecules (peptides and proteins) with 
suitable carriers. These suitable carriers remain a challenge due to the fact that 
bioavailability of these molecules is limited and they get degraded by enzymatic 
action. So the polymeric Nanoparticles  permit encapsulation of bioactive molecules 
and protecting them against enzymatic degradation. 
1.5.4  Nanoparticles for drug delivery in the brain 
In central nervous system the most important factor is Blood brain barrier 
(BBB) for the growth of new drugs and it is characterized by impervious endothelial 
cells with tight junction, enzyme activity and active transport systems. 
Basically the BBB only permits selective transport of molecules. So if we use 
Nan oparticles as targeted drug delivery it will act together with specific receptor-
mediated transport system in BBB. E.g. Polysorbate 80/LDL is capable of delivering. 
So the drugs which cannot easily cross the BBB, can pass easily with the help of 
nanoparticles. 
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There are also other drug delivery systems present for this purpose. 
o Nanoparticles for gene delivery 
o Nanoparticles targeting of epithelial cells etc.29 
Table 2:U.S Patent for Paclitaxel Anti-Cancer Drug 
S.No                         Patent No          Type       Year 
   1.    U.S. Pat. No. 5,641,803,  
U.S. Pat. No. 5,670,537 
Paclitaxel based  
anti-tumor for mulation 
Jan 25, 
2007 
   2. 
 Pat. No. 5,439,686, U.S. Pat. No. 
5,498,421, U.S. Pat. No. 5560933 
Paclitaxel based anti-
tumor formulation 
Oct2. 
2003 
   3. U.S. Pat. No. 5,439,686, U.S. Pat. 
No. 5,498,421, U.S. Pat. No. 
5,560,933 
Process of producing 
Nanoparticles and 
albumin 
Jun 8, 
2006 
   4. U.S.Pat.Nos.5,916,596;6,506,405; 
6,749,868 
Nanoparticle 
Compositions of 
albumin and Paclitaxel 
Jul3. 
2014 
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Review of Literature 
Mamun Ur Rashid et al (2013).,30 developed Silver Nanoparticles (Ag-NPs) 
prepared by using chemical synthesis. Silver nanocolloid solution has been 
prepared chemically by the Precipitation of silver salt using sodium 
borohydride (NaBH4) and trisodium citrate (C6H5Na3O7.2H2O). The 
Nanoparticles were characterized by UV-VIS spectrophotometry and 
Scanning Electron Microscopy (SEM).  
Yujie Wang et al (2002).,31 studied Paclitaxel-loaded Nanoparticles 
incorporated with PVLA were prepared by emulsion solvent evaporation 
method with polyvinyl alcohol (PVA) as co-emulsifier. The presence of 
PVLA on the particle surface was investigated through the change of Zeta 
potential and surface hydrophobicity. Cellular uptake and cytotoxic activity, 
involving factors concerned with them, were evaluated by Hep G2 cells in 
vitro.  
Ngoc Duong Trinh et al (2015).,32 prepared Silver chloride Nanoparticles by the 
precipitation reaction between silver nitrate and sodium chloride in an aqueous 
solution containing poly (vinyl alcohol) as a stabilizing agent. Different 
characteristics of the Nanoparticles in suspension and in lyophilized powder such as 
size, morphology, chemical nature, interaction with stabilizing agent and photo-
stability were investigated. Biological tests showed that the obtained silver chloride 
Nanoparticles displayedantibacterial activities against Escherichia coli and 
Staphylococcus aureus. 
Dinda et al (2013).,33 Formulated Paclitaxel loaded SLNs prepared by 
Solvent emulsification and evaporation method using ultra sonication and 
optimization of critical process variables were carried out to develop stable 
SLNs. The average particle size of SLNs was found to be 63 nm ± 5.77 with 
Poly dispersity index (PDI) 0.272 ± 0.02 and entrapment efficiency was 
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found 94.58%. The stability studies and zeta potential were performed at 
refrigerated temperature (2-8°C) indicating no significant increase in particle 
size after one month storage. In-vitro release studies showed initial burst 
release followed by controlled release for 48hrs (about 73%). 
Shu-Ben Sun et al (2015).,34 prepared Capecitabine NPs were characterized 
by FT-IR, DSC, drug Loading, entrapment efficiency, particle size, surface 
morphology by Atomic Force Microscopy (AFM), X-ray diffraction and in-
vitro studies. FT-IR and DSC studies indicated that there was no interaction 
between the drug and polymer. The morphological studies performed by 
AFM showed uniform and spherical shaped discrete particles without 
aggregation and smooth in surface morphology with a nano size range of 144 
nm. X-ray diffraction was performed to reveal the crystalline nature of the 
drug after encapsulation.  
Natarajan Tamilselvan et al (2015).,35 Formulated anti-alzheimers drug 
loaded chitosan Nanoparticles by simple ionic gelation method using various 
concentrations of chitosan and TPP. The prepared Nanoparticles were 
evaluated for particle size, shape, charge, encapsulation efficiency, in vitro 
drug release and in vitro cytotoxicity. Results: The optimized drug loaded 
Nanoparticles showed the size of 125 ± 4mn with PDI 0.25 ± 0.05, potential 
of +40 ± 2mV, encapsulation efficiency of 65.5 ± 1.2% and the drug release 
of 68.4 ± 1.6% with an initial burst effect up to one hour followed by 
sustained release up to 24 hrs. Further the optimized formulation was 
subjected to investigate the cytotoxicity of CS-NP in SH-SY-5Y cell lines it 
revealed that the cell viability was above 90% without any toxicity. 
CA Anuradha et al (2010).,36 has studied Bis-demethoxy Curcumin 
Analogue (BDMCA) Nanoparticle formulations were fabricated by a double 
emulsion solvent evaporation technique using polycaprolactone as the 
polymer. The Nanoparticles were characterised for drug content, particles 
size, in vitro drug release and the drug-polymer interaction. The in vivo 
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properties of the formulations in male Wistar rats were evaluated from the 
pharmacokinetics and pharmacodynamics of BDMCA following i.v. 
administration of the Nanoparticles. BDMCA solution was administered i.v. 
as a reference. Hepatoprotectivity of the formulation was determined in  
treated rat model. 
Jiaojiao Xu et al (2015).,37 developed Nanoparticles for Chronic intracellular 
infections caused by drug-resistant Pathogens pose a challenge to the treatment of 
chronic osteomyelitis is. The results showed that the prepared Cefixime Nanoparticles 
were predominantly spherical in shape with  an average par ticle diameter of 220 nm, 
a positive zeta potential, and a loading   efficiency of 73.65% ˘1.83%. Furthermore, 
their drug release profile followed the Higuchi model for sustained release, with non-
Fickian diffusion.  
Shanmuganathan Seetharaman et al (2016).,38 prepared Cefixime 
Nanoparticles by the modified-coacervation method. The prepared drug 
Nanoparticles were evaluated for particle size, zeta potential, surface 
morphology, entrapment efficiency, in-vitro drug release studies and also in-
vitro antimicrobial efficiency studies for the selected ideal batch. The surface 
morphology of the prepared Nanoparticles was found to be spherical with 
smooth surface and entrapment efficiency was found to be 70.4±1.2 to 
83.4±2.0. The in-vitro drug release showed a biphasic pattern with initial 
burst release followed by the sustained release of the drug up to 24h.  
YI Yi-Mu et al (2015).,39 prepared 5-FU sodium alginate bovine serum 
albumin Nanoparticles by Emulsion solidification method, and to determine 
its diameter under Transmission Electronic Microscope (TEM). Then the rate 
of NP and external drug releasing velocity were measured. The average 
arithmatic diameter of the NP was 166nm±34nm, the rate of 5-FU was 32.8% 
and the cumulative external releasing ratio amounted to 84.0% within 72 
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hours. The NP was mainly distributed in the liver, spleen, lungs and kidneys 
after NP oral administration to rats.  
Shashank Tummala et al (2015).,40 prepared Carbamazepine NP. The 
polymeric Nanoparticles were subjected to particle size evaluation, SEM 
study, drug content, entrapment efficiency and in vitro release studies. 
Nanoparticles with drug: polymer ratio of 1:1 has shown a particle size, drug 
loading and entrapment efficiency of 130±2.1nm, 61.28% and 18.15% 
respectively. Optimized batch in drug: polymer ratio of 1:1 has shown a 
particle size, drug loading and entrapment efficiency Contour plots and 3D-
scatter plots were drawn for statistical supportive evaluation in optimization 
using Minitab 17. 
Pragati Lingwal et al (2015).,41 prepared Ampicillin Nanoparticles by 
Desolvation method and characterized for drug content, particle size and size 
distribution, zeta potential, and in vitro drug-release study. In this method the 
Bovine Serum Albumin Nanoparticles were prepared by Desolvation 
technique. Ampicillin belonging to the Penicillin group of beta-lactam 
antibiotics. It is used for the treatment of infections known to be or highly 
likely to be caused by bacteria. All formulations were further checked for 
evaluation parameters. Particle size of all formulation was found to be 200 to 
500nm. Zeta potential for all formulated Nanoparticles were in the range of 
64.1which indicates excellent stability.  
Vyjayanthimala et al (2014).,42 studied Nanoparticles of Zidovudine using 
chitosan, liquid paraffin and Tween-20 using Emulsion droplet coalescence 
method. The concentration of the polymer Chitosan was selected based on 
the results on preliminary screening. The Nanoparticles prepared were 
evaluated for morphology, loading efficiency and in vitro release. The 
particle shape and morphology of the prepared Zidovudine Nanoparticles 
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were determined by SEM analysis. The amount of Zidovudine entrapment in 
the Nanoparticles was calculated by the difference between the total amount 
of drug added to the Nanoparticle and the amount of non-entrapped drug 
remaining in the aqueous supernatant. A Franz diffusion cell. 
Shumaia Parvin et al (2014).,43 SLNPs are prepared by hot homogenization 
method at different ratio of drug, lipid, surfactant and stabilizer and 
designated as DNP1 to DNP6. In vitro dissolution study was performed using 
the USP type II apparatus (paddle method) at 50 rpm to a temperature of 
37°±0.5°C in distilled water containing 0.75% w/v SLS (sodium lauryl 
sulfate). The absorbance of sample was measured spectrophotometrically at 
Ȝmax 239nm on a UV-Visible spectrophotometer. Release pattern of drug 
was found to follow zero order, first order and Korsmeyer-Peppas equations.  
Anand Kumar Kushwaha et al (2013).,44 prepared Raloxifene loaded SLN 
by solvent emulsification/evaporation method, and different concentrations of 
surfactant, and homogenization speed were taken as process variables for 
optimization. SLN were characterized for particle size, zeta potential, 
entrapment efficiency, surface morphology, and crystallinity of lipid and 
drug. In vitro drug release studies were performed in phosphate buffer of pH 
6.8 using dialysis bag diffusion technique. Particle sizes of all the 
formulations were in the range of 250 to 1406 nm, and the entrapment 
efficiency ranges from 55 to 66%. FTIR and DSC studies indicated no 
interaction between drug and lipid, and the XRD spectrum showed that RL-
HCL is in amorphous form in the formulation.  
Riddhi Dave et al (2012).,45 prepared and evaluated Chitosan Nanoparticles 
containing Doxorubicin by the w/o emulsion method. SEM indicated 
spherical structure of Nanoparticle without agglomeration. In vitro drug 
release study suggests sustain drug release for a longer period of time. In 
particle size analysis, it was found to be in nano range 210 nm which shows 
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the formation of Nanoparticle with uniform size distribution. The drug 
entrapment was found to be 53.12% in optimized batch. The release shows 
that the drug entrapped within the polymeric matrix and it follows peppas 
diffusion controlled mode. 
Can Zhanga et al (2008).,46 used Bovine serum albumin (BSA) to prepare 
the microspheres loading with 5-Fluorouracil (5-FU) by means of chemical 
crosslinking method and then the microspheres were coated with N-
galactosylated chitosan by electrostatic interaction. The structure of coating 
layers on the surface of 5-FU-loaded BSA microspheres was characterized by 
attenuated total reflection Fourier (ATR-FTIR), electron spectroscopy for 
chemical analysis (ESCA), wide X-ray diffraction (WXRD) and transmission 
electron microscopy (TEM). The properties of the coated microspheres 
containing 5-FU were determined.  
C. Zinuttia et al (2003).,47 developed Ethylcellulose microspheres 
containing 5-fluorouracil (5-FU) by a solvent evaporation technique using 
light mineral oil as the continuous phase. The drug was suspended in the 
acetone solution of the polymer. Three drug/polymer ratios (1/1, 1/2 and 1/3) 
were utilized. The microspheres were studied with respect to size, drug 
content and surface characteristics; the higher the polymer content, the 
smoother the microspheres. The drug was suspended in the polymer and the 
drug loading was important (more than 90%) with the three types of 
microspheres.  
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Drug Profile 
3.1  Drug Profile48, 49, 50 
3.1.1  Description 
 Paclitaxel is a compound extracted from the Pacific yew tree Taxus brevifolia 
with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of 
microtubules, thereby resulting in the inhibition of cell division. This agent also 
induces apoptosis by binding to and blocking the function of the apoptosis inhibitor 
protein Bcl-2 (B-cell Leukemia 2). (NCI04). 
Source: MeSH 
Record Name: Paclitaxel 
 
Chemical name    - Paclitaxel; TAXOL; Taxol A; Abraxane; Paxene;  
    Paxceed  
Molecular formula   - C47H51NO14 
Molecular weight  - 853.91g/mol 
Category  - Antimicrotubule agent 
Physical and chemical properties 
Colour   - White to off-white crystalline powder 
Form   - Fine white powder 
Odour   - Odourless 
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State   - Solid 
pKa   - 10.36 
Melting temperature - 216-217 °C 
LogP   - 3 
Log s   - -5.2 
3.1.2  Solubility 
Soluble in methanol (50 mg/ml - clear, colorless solution), DMSO (50 mg/ml - 
clear, colorless solution), chloroform and ethanol. DMSO solutions can be stored 
aliquoted and frozen at -20°C for several months. Paclitaxel undergoes 
transesterification in methanol, and it hydrolyzes in aqueous solutions; Hardly soluble 
in water. 
 3.1.3 Mechanism of action  
 Paclitaxel interferes with the normal function of microtubule growth. Whereas 
drugs like colchicine cause the depolymerization of microtubules in vivo, 
paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their 
structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. 
Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building 
block" of mictotubules, and the binding of paclitaxel locks these building blocks in 
place. The resulting microtubule/paclitaxel complex does not have the ability to 
disassemble. This adversely affects cell function because the shortening and 
lengthening of microtubules (termed dynamic instability) is necessary for their 
function as a transportation highway for the cell. Chromosomes, for example, rely 
upon this property of microtubules during mitosis. Further research has indicated 
that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding 
to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its 
function. 
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3.1.4  Pharmacokinetics (ADME): 
Paclitaxel is a taxane. Paclitaxel binds to tubulin, the protein component of 
microtubules, simultaneously promoting their assembly and disassembly to form 
stable, nonfunctional microtubules. Although some reports indicate a cross-reactivity 
rate of 90% between docetaxel and paclitaxel, others suggest it does not occur 
consistently. Stabilization of microtubules blocks cells in the M phase of the cell 
cycle, inhibiting cell division and causing cell death. Paclitaxel acts as a 
radiosensitizing agent by blocking cells in the G2phase. 4 Paclitaxel is an 
immunosuppressant.                                   
3.1.5  Adverse Effects 
Emetogenic potential : Low 
Extravasation Potential :  Irritant  
                          Table 3: Side Effect of Paclitaxel Nanoparticles  
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3.2. Drug Interactions  
Paclitaxel, belonging to the class of taxanes, has demonstrated extraordinary 
activities in clinical trials against a variety of tumors, including gastric cancer, colon 
cancer, breast cancer etc. Paclitaxel is a mitotic spindle poison that accelerate the 
microtubule assembly from tubulin and block the depolymerization of the 
microtubule.  
Paclitaxel is presently formulated as Taxol, a concentrated solution containing 
6 mg of paclitaxel/ml of Cremophor EL. (Polyoxyethylated castor oil and ethanol, 
50% v/v) that must be further diluted before administration. 
The major drawbacks associated with paclitaxel are, severe side effects such 
as, toxic effects on bone marrow, neutropenia, hypersensitivity reactions, limited 
water solubility etc. 
Hence in present work an attempt is being made to provide an alternative drug 
delivery system having improved therapeutic index for paclitaxel in the form of novel 
polymeric thermosensitive micellar delivery system which have following 
advantages,  
 Improved site specificity. 
 Localization of the drug in the tumor cells by thermal targeting. 
 Reduce risk of unwanted side effects. 
 Increase bioavailability and hence smaller dosage form size. 
 Possibility of higher dosage without side effects. 
 More effective cancer treatment. 
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Table 4: Drug Interactions of Paclitaxel 
 
3.3 Precautions 
Caution 
 Preexisting liver impairment may impair elimination of paclitaxe reduction is 
suggested 
Special populations 
 Elderly patients may have more myelosuppression, neuropathy and 
cardiovascular toxicities 
 Patients with AIDS-related Kaposi’s sarcoma may have more hematologic    
toxicities, infections and febrile neutropenia. 
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Carcinogenicity 
 No information found  
Mutagenicity 
 Not mutagenic in Ames test and mammalian in vitro mutation test. Paclitaxel 
is clastogenic in human lymphocytes in vitro but not in other mammalian in vivo 
chromosome tests.  
Fertility 
 In animal studies, reduced fertility has been observed, with decreased 
pregnancy rates and increased embryo loss in females and testicular atrophy / 
degeneration in males. 
Pregnancy 
 FDA Pregnancy Category D.5,10 There is positive evidence of human fetal 
risk, but the benefits from use in pregnant women may be acceptable despite the risk 
(e.g., if the drug is needed in a life-threatening situation or for a serious disease for 
which safer drugs cannot be used or are ineffective). Paclitaxel has shown to be 
embryotoxic and fetotoxic in animal studies; soft tissue and skeletal malformations 
have been reported.  Breastfeeding is not recommended due to the potential secretion 
into breast milk. 
3.4.  Side effects 
  Low blood counts.  Your white and red blood cells and platelets may 
temporarily decrease.  This can put you at increased risk for infection, 
anemia and/or bleeding. 
 Hair loss 
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 Arthralgias and myalgias, pain in the joints and muscles. Usually 
temporary occurring 2 to 3 days after Taxol, and resolve within a few 
days.   
 Peripheral neuropathy (numbness and tingling of the hands and feet) 
 Nausea and vomiting (usually mild) 
 Diarrhea 
 Mouth sores 
 Hypersensitivity reaction - fever, facial flushing, chills, shortness of 
breath, or hives after Taxol is given.  The majority of these 
reactions occur within the first 10 minutes of an infusion.  Notify your 
healthcare provider immediately (premedication regimen has 
significantly decreased the incidence of this reaction).  
 The following are less common side effects (occurring in 10-29%) for patients                  
            receiving Taxol: 
 Swelling of the feet or ankles (edema). 
 Increases in blood tests measuring liver function.  These return to normal 
once treatment is discontinued. (see liver problems). 
 Low blood pressure (occurring during the first 3 hours of infusion). 
 Darkening of the skin where previous radiation treatment has been given 
(radiation recall - see skin reactions). 
 Nail changes (discoloration of nail beds - rare) (see skin reactions). 
3.5  Uses 
 Primary use: 
 Breast cancer 
 Lung cancer-non small cell. 
 Ovarian cancer, 
 Kaposis sarcoma.  
29 
               Other uses: 
 Lung cancer. 
 Esophageal cancer. 
 Bladder cancer. 
 Head and neck cancer. 
 Cervical cancer. 
 Endometrial cancer. 
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Aim of the present investigation 
 
Drug delivery systems to the colon are being actively investigated in order to develop 
oral preparations of peptides and treat local colonic diseases, e.g., irritable bowel 
syndrome, ulcerative colitis, cancer, and infection. 
Paclitaxel is a microtubule-stabilizing agent which promotes polymerization of 
tubululin causing cell death by disrupting the dynamics necessary for cell division. It 
has neoplastic activity especially against primary epithelial ovarian carcinoma, breast, 
colon, and non-small cell lung cancers. Paclitaxel is poorly soluble in aqueous 
solutions but soluble in many organic solvents such as alcohols. It therefore lends 
itself well to more advanced formulation strategies. In the present investigation, an 
attempt was made to prepare Paclitaxel Silver Nanoparticle by precipitation 
technique. In order to stabilize the size of particle, various concentrations of Silver 
nitrate and Trisodium citrate to be used. Prepared Nanoparticle to be optimized by 
their encapsulation efficiency, particle size and Release rate. Zeta potential and SEM 
study also included in the investigation. A short term stability study proposed for 
optimized formulation. 
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Plan of Work 
1. Literature survey 
a) Selection of drug 
b)    Selection of polymers 
      c)    Selection of suitable method 
2. Procurement of Drug, Polymer and excipients. 
3. Raw material Analysis. 
4. Preformulation studies 
       a) Solubilitystudy. 
       b)  Comparatibility studies- The drug and polymer compatibilitycan be done 
with the FTIR. 
5. Construction of Calibration Curve. 
6. Preparation of paclitaxel Nanoparticle by Precipitation Technique. 
7.  In vitro drug release study for prepared Nanoparticles. 
8. Determination of Particle Size Analysis and Encapsulation Efficiency. 
9. Analysis for Zeta Potential. 
10. SEM Analysis. 
11. Stability Study. 
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Materials and Methods 
          Materials used in the formulation of Paclitaxel silver Nitarte Nanoparticles. 
Table 5 
Manufacturers/Suppliers                      Materials 
Salius Pharma Pvt.Ltd (Mahapi Navi 
Mumbai) 
Paclitaxel 
Merck Life Science Private Limited 
(Mumbai) 
Silver Nitrate 
Thermo Fisher Scientific India Pvt. Ltd 
(Mumbai) 
Tripoly Citrate (TPP) 
Changshu Hongsheng Fine Chemical 
Co.Ltd .(China) 
Methanol 
S.D.Fine chemicals Ltd (Mumbai) Acetone 
S.D.Fine chemicals Ltd (Mumbai) Dichloromthane 
Chemspure (Chennai) Isopropyl  alcohol 
S.D.Fine chemicals Ltd (Mumbai) N-hexane 
S.D.Fine chemicals Ltd (Mumbai) Buty 4- Aminobenzoate(Butamben) 
S.D.Fine chemicals Ltd (Mumbai) Starch 
Chemspure (chennai) Hydroxy propyl Methyl cellulose 
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Equipments used in the formulation of Paclitaxel silver Nitrate Nanoparticles 
Table 6 
Manufacturer Instruments 
Axis,India Digital balance  
Electrolab India Pvt Ltd Dissolution testing apparatus  
Shimadzu Analytaical (India) Pvt 
Ltd  
UV-Visible spectrophotometer 
ABB Bomem ,Quebee,Canada  Fourier Transform Infrared 
Spectroscopy 
FEI,Quanta 200 SEM,USA Scanning Electron Microscop (SEM) 
Sigma instruments (Chennai) Heating Mantle 
Sigma scientific product ,Chennai Sigma Humidity Chamber(40C 
75%/RH) 
SHIMADZU SPD-20 A(PDA 
Dector),India 
High Performance Liquid 
Chromatography(HPLC) 
(Beckman Coulter Delsa Nano C, 
Brea, USA). 
Particle size analyzer 
(Beckman Coulter Delsa Nano C, 
Brea, USA). 
Zeta potentiometer 
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6.1 Raw material analysis of Paclitaxel:48  
6.1.1  Description: 
White colour powder ;odourless. 
6.1.2 Melting point: 
Melring point of Paclitaxel was determined by capillary method. 
6.1.3  Precentage purity:48 
Assay: 
 Procedure—separately an equal volumes were injected (about 10 µL) of 
theStandard preparationand theassay preparationinto the chromatograph, the 
chromatograms was recorded, and measured the areas for the major peaks. The 
quantity was calculated, in mg, of C47H51NO14 in the portion of Paclitaxel taken by 
the formula: In which C is the concentration, in mg per ml, of USP Paclitaxel RS in 
the Standard preparation;and ru and rs are the peak responses for paclitaxel obatined 
from the assay preparation and the satandard preparation,respectively. 
6.2 Identification test for paclitaxel 
       Table 7 : Identification test of paclitaxel 
S.No Test   Method  
 1. Infrared Absorption As per USP 
   2. Retention Time  As per USP 
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6.3 Organoleptic Characteristics 
The color, odor, and taste of the drug were characterized and recorded using 
descriptive terminology. 
6.4  Preformulation Studies: 
Preformulation is defined as the stage of research and development process 
where physical, chemical and mechanical properties of a new drug substance are 
characterized alone and when combined with excipients in order to develop stable, 
safe and effective dosage form.51 
A thorough understanding of physicochemical properties may eventually 
provide a rationale for formulation design or carry, the need for molecular 
modification or purely confirms that there are no significant barriers to the compound 
development. Hence, preformulation studies were performed on the obtained sample 
of drug for solubility analysis, identification and compatibility studies. 
6.4.1 Solubility analysis 
The solubility of Paclitaxel was performed by using traditional shaker agitator.100 mg 
of Paclitaxel was added to 5 ml of methanol and was shaken on a mechanical shaker 
for 48 hours at 370C. After 48 hours , the resultant saturated dispersion in filtered 
using 0.45 µfilter followed by 0.2 µ filter to exclude the undissolved solids.The 
filtrate obtained was diluted appropriately using suitable solvent and estimated for 
drug content using UV spectrophotometer/HPLC. 
6.4.2 FTIR Spectral analysis50 
FTIR spectral analysis of pure drug and polymers was carried out and observation 
was made whether changes in the chemical constitution of drug after combining it 
with the polymers occurred. About 2 mg of the samples were mixed with potassium 
bromide of equal weight and crushed to get pellets applying pressure on 600 Kg/cm2 
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and scanned with the IR instrument (Shimadzu, 8400 Series,Tokyo, Japan) from 400-
4000cm-1. 
6.4.3 Calibration curve  
The calibration curve for paclitaxel was prepared by using phosphate buffer (pH 
7.4).Phosphate buffer pH 7.4 
Phosphate buffer was prepared by placing 25ml of 0.2M potassium dihydrogen 
orthophosphate solution and 19.55ml of 0.2N sodium hydroxide solution in a 100ml 
volumetric flask and volume was made up to the mark with distilled water. The pH 
was found to be 7.4±0.1. 
Primary stock solution for paclitaxel with phosphate buffer (pH 7.4) 
Accurately weighed 100mg of paclitaxel was dissolved in 10ml of methanol in 
a 100ml of volumetric flask and volume was made up to the mark with pH 7.4 buffer 
to get a concentration of 1000µg/ml. 
Secondary stock solution for phosphate buffer (pH 7.4) 
From primary stock solutions of phosphate  buffer  10ml was pipetted out in a 
100ml of volumetric flask and volume was made up to the mark with pH 7.4 buffer to 
obtain a concentration of 100µg/ml. 
From secondary stock solutions, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5 and 
5.0ml were piped out and diluted to 10ml with respect buffers to get a concentration 
range from 5µg/ml to 50µg/ml. Then it was analyzed spectrometrically at 220nm. 
The calibration curve was plotted with the absorbance Vs concentration 
(µg/ml). 
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6.5  Method of preparation for Paclitaxel silver nitrate Nanoparticles by                                  
 precipitation Technique: 
 
 Silver nitrate and trisodium citrate were used as starting materials for the 
preparation of Paclitaxel silver nitrate Nanoparticles (NP). The silver colloid was 
prepared by using chemical Precipitation method. All solutions of reacting materials 
were prepared in distilled water. In typical experiment 50 ml of 0.001 M AgNO3 was 
heated to boil. To this solution 5 mL of Paclitaxel (150 mg/5 ml of methanol) solution 
was added followed by addition of 5 ml of 1 % of trisodium citrate added drop by 
drop. During the process, solutions were mixed vigorously and heated until change of 
color was evident (pale yellow). Then it was removed from the heating device and 
stirred until cooled to room temperature. The colloidal solution of silver Nanoparticles 
were characterized by using UV-Visible spectroscopy and SEM. The entire addition 
process took about 3 minutes, after which the stirring was stopped and the stir bar was 
removed. Reaction conditions including stirring time and relative quantities of 
reagents (both the absolute number of moles of each reactant as well as their relative 
molarities) must be carefully controlled to obtain stable yellow colloidal silver. If 
stirring was continued once all of the silver nitrate was added, aggregation began as 
the yellow solution first turned to darker yellow then violet and eventually grayish 
after which the colloid broke down and particle settled out. 
 
     Fig.7: Diagrammatic Representation of Method of Preparation of                  
                 paclitaxelNanoparticles By preciptation  Method.   
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               Fig.8: Photograph showing the preparation of Nanoparticles 
 
 
Fig.9: Silver Nitarte Nanoparticles Product 
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Table 8: List of excipients and their use 
S.No Name Use 
1        Paclitaxel Anti-Cancer 
2       Silver nitrate Natural Polymer 
5 Dichloromethane Organic solvent 
6      Trisodium citrate  Crosslinking agent 
8      Methanol Organic solvent 
 
           Table 9:  Formulationtablefor Paclitaxel Nanoparticles 
Formulation 
Code 
Drug 
(mg) 
AgNO3 
(mg) 
 
Molarity 
 
Methanol 
Trisodium 
citrate 
(1%w/w) 
 
PXN1 150 0.017gm 0.0001M  5 5 
PXN2 150 0.17gm 0.001M 5 5 
PXN3 150 0.5gm 0.003M 5 5 
PXN4 150 0.8 gm 0.004M 5 5 
PXN5 150 1.0 gm 0.005M 5 5 
PXN6 150 1.17gm 0.00688M 5 5 
PXN7 150 1.17gm 0.00688M 5 10 
PXN8 150 1.17gm 0.00688M 5 3 
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 6.6     Evaluation of Paclitaxel silver nitrate Nanoparticles: 
6.6.1  Apparent bulk density: 
The bulk density was determined by transferring the accurately weighed 
sample of powder to the grounded cylinder. The initial volume and weight was noted. 
Ratio of weight of sample was calculated by using the formula  
Density= Mass/Volume 
6.6.2  Tapped density: 
 Weighed powder sample was transferred to graduated cylinder and was placed 
on the tap density apparatus, was operated for fixed number of taps (500 times).The 
density was determined by the formula. 
Density=Mass/Tapped Volume 
6.6.3 Carr’s Index: 
 Based on the poured density and tapped density, the percentage 
compressibility of the granules was computed using the carr’s index by the formula 
and the carr’s index value and its specifications are given in Table10 
      Tapped density - Bulk density 
Carr’s index    =          x100 
                                                                    Tapped density  
 
Table 10: Carr’s index value 
S No    %compressibility          Type of flow 
1  5-15             Excellent 
2 12-16              Good 
3 18-21              Fair  
4 23-25              Poor 
5 33-38           Very poor 
6 <40         Extremely poor 
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6.6.4   Haunser’ s ratio 
It indicates the flow properties of the powder and is measured by the ratio of tapped 
density to bulk density Table 11 
                                        Tapped density 
Hausner's ratio =      _______________ 
                                                                 Bulk density  
 
Table 11 : Haunser's ratio 
Haunser's ratio Type of flow 
>1.25 Good flow 
<1.25 Poor flow 
 
6.6.5 Porosity:  
Paclitaxel powder is placed in a graduated cylinder and the total volume is 
noted. The volume occupied is known as the bulk volume, Vb. If the powder is 
nonporous, that is ,has no internal pores or capillary spaces, the bulk volume of the 
powder consists of the true volume of the solid particles plus the volume of the spaces 
between the particles. The volume of the spaces, known as the void volume v,is given 
by the equation  
V= Vb _ Vp 
Where Vp is the true volume of the particles. The method for determining the volume 
of the particles will by given later. 
The porosity or voids. Of the powder is defined as the ratio of the void volume to the 
bulk volume of the packing: 
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6.6.6 Drug content and encapsulation efficiency55 
Precisely weighed 100mg of Paclitaxel Silver Nitrate Nanoparticles were 
crushed in a mortar and suspended in 100ml of phosphate buffer (pH 7.4) and kept in 
sonication for 2hrs. Then the samples were centrifuged at 1000rpm for 20mins to 
remove the supernatant layer, if any. The samples were filtered. From this filtered 
solution 1 ml of sample was withdrawn and diluted to 100 ml with phosphate buffer 
(pH 7.4). Then it was analyzed spectrophotometrically at 271nm. 
6.4.10  Drug content: 
Theoretical drug content     =Weight of drug loaded / Total weight of Nanoparticles 
Practical drug content = Concentration X dilution factor X Conversion factor 
Encapsulation efficiency    = (Actual drug content / Theoretical drug content) X 100
     
6.7 In-vitro Drug Release Studies56 
In vitro release of Paclitaxel Silver Nitrate Nanoparticles was conducted by a 
dialysis membrane having a pore size of 2.4 mm (LA-395-5Mt Himedia Pvt. Ltd, 
Mumbai, India) with 75 ml of pH 7.4 phosphate buffer at 37°C. Briefly in a 100 ml 
beaker 75ml of pH 7.4 phosphate buffer was taken. A 2 ml of formulation was taken 
into a dialysis bag and dipped into the buffer solution. The dialysis membrane was 
activated earlier using by soaking in 1% w/v NaOH overnight. The flask was kept on 
a magnetic stirrer. Stirring was maintained at 250 rpm and the temperature of the 
buffer was maintained at 37°C. Sampling was done by withdrawing 1 ml of aliquots 
from a beaker. Immediately 1 ml of new buffer was added to keep the sink condition. 
Samples were analyzed after sufficiently diluting with methanol by using a 
UV/Spectrophotometer (UV/VIS-Double beam Spectrophotometer, V-530, Jasco, 
Tokyo, Japan) at a wavelength of 271 nm. Each test was conducted thrice and average 
value taken for the calculation. 
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Fig.10: Dialysis Membrane 
6.7.1 Amount of drug present  
= Concentration × Dilution factor × Conversion factor × Amount of stock solution. 
                                                                           Amount of drug present         
Cumulative % drug release =        __________________________   X 100 
                                                 Amount of drug to be present  
 
The release data obtained were fixed into various mathematical models like 
zero order, First Order, Higuchi and Korsmeyer-Peppas to know which mathematical 
model was best fitting the obtained release profile. 
6.7.2 Kinetic study: Zero order release 
In order to analyze the release mechanism, several release models were 
experiencing such as 
Zero order Qt = Q0+K0t 
Where, Qt is the amount of drug released at time t,  
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K0 is the apparent dissolution rate constant or zero order release constant and  
Q0 is the initial concentration of the drug in the solution resulting from a burst 
effect; in this case the drug release runs at a constant rate. 
It describes the systems where the drug release rate is autonomous of its 
concentration of the dissolved substance. 
A graph is plotted between the time taken on x-axis and the cumulative % of 
drug release on y-axis and it gives a straight line. 
6.7.3 Application in  first order release: 
 This relationship can be used to describe the drug dissolution of several types 
of modified release pharmaceutical dosage forms, as in the case of some transdermal 
systems, as well as matrix tablets with low soluble drugs in coated forms, osmotic 
systems, etc .57, 58 
The release of the drug which followed first order kinetics can be expressed by 
the equation: 
dc/ dt = -Kc  (1) 
Where K is first order rate constant expressed in units of time-1. 
Equation (1) can be expressed as: 
log C = log C0 - Kt / 2.303 (2) 
Where C0 is the initial concentration of drug, k is the first order rate constant, 
and t is the time. The data obtained are plotted as log cumulative percentage of drug 
remaining vs. time, which would yield a straight line with a slope of -K/2.303. 
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6.7.4 Application in Higuchi release equation: 
This relationship can be used to explain the drug dissolution in pharmaceutical dosage 
forms such as those containing water-soluble drugs in permeable matrices.59, 60 
The Higuchi release equation is 
Q = KHt1/2 
Where  
Q is the cumulative amount of drug release at time “t” 
KH is Higuchi constant 
T is time in hours 
The Higuchi equation suggests that drug release by diffusion. 
A graph is plotted between the square root of time taken on x-axis and the 
cumulative percentage of drug release on y-axis and it gives a straight line. 
6.7.5 Application in korsmeyer-peppa’s equation :  
 This relationship can be used to illustrate the drug dissolution from several 
types of modified release pharmaceutical dosage forms, as in the case of some 
transdermal systems and matrix tablets with water soluble drugs.61, 62 
The korsmeyer-peppas equation was given as 
F = (Mt/M) = Kmtn 
Where 
F is fraction of drug released at time‘t’ 
Mt is amount of drug release at time‘t’ 
M is total amount of drug in dosage form 
Km is kinetic constant 
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n is diffusion or release exponent 
t is time in hours 
n is estimated from linear regression of log ( Mt/M)  versus log t 
If n = 0.45 it indicates fickian diffusion 
0.45<n<0.89 it indicates anomalous diffusion or non-fickian diffusion 
Anomalous diffusion or non-fiction diffusion refers to a combination of both 
diffusion and erosion controlled rate rules. 
A graph was plotted between the log time release on x-axis and the log 
cumulative percentage of drug release on y-axis and it gives a straight line. 
Interpretation of drug release mechanism is given in following Table 12. 
Table 12: Interpretation of Drug Release Mechanism 
Release exponent (n) Drug release mechanism Rate as a function of time 
0.5 Fickian diffusion t -0..5 
0.5 < n <1 Anomalous transport t n-1 
1 Case-II transport Zero order release 
> 1 Super case II transport t n -1 
 
.6.7.6    SEM Analysis52 
Scanning electron microscopy (JEOL 5400, Tokyo, Japan) was used to decide 
the shape, surface topography and texture as well as to inspect the morphology of 
cracked or sectioned surface. SEM is a frequently used method for characterizing 
drug delivery systems, owing in large part to simplicity of sample preparation and 
ease of operation. Sample spreads on the small square plate and coated with a gold ion 
for 5-6 mins. The prepared sample was kept inside the chamber and images captured 
with different magnifications.( 10,000, 15,000 and 20,000) 
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6.7.7Particle Size Analysis (PSA)53 
The size division of the Nanoparticles was determined using the particle size 
analyzer (Beckman Coulter, Delsa nano C, Brea, USA) prepared with a dry accessory 
system. About 2ml of the prior prepared suspension has to be transferred into a 4.5 ml 
disposable plastic cuvette, placed in the analysis device and subsequent analyzed for 
size analysis and temperature maintained at 25°C. 
6.7.8    Zeta Potential Analysis54 
The zeta potential was measured using the appropriate instrument (Beckman Coulter 
Delsa Nano C, Brea, USA).using automatic titration regime that adjusts the pH of the 
sample to pre-defined values by adding 0.1M HCL or 0.1M NaOH titrator a volume 
of 20 ml suspension is necessary. 
Zeta Potential (mV) Stability behavior of colloid 
From 0 to ±5 Rapid coagulation or Flocculation 
From ±10 to ±30 Incipient instability 
From ±30 to ±40 Moderate stability 
From ±40 to ±60 Good stability 
More than ±61 Excellent stability 
 
 
 
 
6.7.9       Stability studies : 
 
          The objective of the stability testing is to show evidence as how the quality of 
the drug substance or product varies with time under the influence of variety of 
environmental factors such as temperature, humidity and light to establish a reset for 
the drug substance or a shelf life for the drug product and recommended storage 
condition. 
                Stability of a drug is defined as the ability of a particular formulation, in a 
specific container, to remain within its physical, chemical, therapeutically and 
toxilogical specifications. 
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              The optimised batch paclitaxel silver nitare Nanoparticles were subjected for 
accelerated stability studies. The Paclitaxel Nanocapsule from the batch of 
PXN6filled in the capsule (size1) equivalent to 150 mg. Lactose was used as diluent 
to make up total weight of capsule as 290 mg (161+129).The Paclitaxel Nanocapsules 
were kept in in sigma stability chamber. The samples were analysed at 0,1 and 2 
months intervals. The data was analysed for any significant changes from the initial 
data. The following test  were performed: 
 
1. Test for physical parameters 
2. Assay 
3. In-vitro dissolution study. 
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Results 
7.1  Raw material analysis of Paclitaxel:51 
7.1.1  Description: 
White colour powder ;odourless. 
7.1.3  Precentage purity: 
Assay: Identification test for paclitaxel    
Table 13: Identification test of paclitaxel 
S No                       Test    Method  
   1. Infrared Absorption As per USP 
   2. Retention Time  As per USP 
 
7.2 Preformulation Studies: 
7.2.1  Organoleptic Characteristics 
 The color, odor, and taste of the drug were characterized and recorded using 
descriptive terminology; the results were shown in the Table 14. 
          Table 14: Organoleptic Charecteristics of Paclitaxel 
Properties Result 
Odour Odourless 
Colour White to off-white 
Form Crystalline 
 
7.2.2 Melting point 
                        Table 15: Melting point of the pure paclitaxel 
Sample Reported Observed 
Paclitaxel 216-217 °C 0C 
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7.2.3  Solubility :  
Table 16:Solubility of Paclitaxel in different solvents. 
S.No Solvent Pure Drug   Solubility 
1. Methanol ( 50 mg/ml) Freely soluble 
2. Dichloromethane (5mg/ml) Soluble 
3. Ethanol (1.5mg/ml) Soluble 
4. Octanol (0.4mg/ml) Slightly soluble 
5. Ethyl acetate (0.25mg/ml) Slightly soluble 
6. Water (10-20 µM) Poorly soluble  
  
7.4  FT-IR spectral analysis 
The FT-IR analysis of the drug and polymer gave thermal profile charecterstic 
of the substances.  
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Fig.11: FTIR Spectrum of Pure Drug paclitaxel 
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Fig.12: FTIR Spectrum of  Formulation paclitaxel 
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Table 17 : Comparison of FTIR peaks of drug and polymers 
S.No Formulation Wave number (cm-1) 
1 Pure Drug paclitaxel 3437.26, 2928.04, 2341.66, 1724.42, 1647.26, 
1369.50, 1244.13, 1070.53, 709.83 
2 Paclitaxel silver nitrate 
particle 
3437.26, 2341.66, 1724.42, 1244.13, 1070.53, 
709.83 
 
8.3 Standard calibration curve of paclitaxel in (pH 7.4) buffer solutions at 
 265nm: 
 
Fig.13: Ȝmax of  in pH 7.4 at 220nm 
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Table 18: Obervations for Standard graph of  in pH 7.4 at 220nm 
Sl.No Concentration (µg/ml) Absorbance 
1 0 0 
2 0.3 0.156 
3 0.6 0.295 
4 0.9 0.451 
5 1.2 0.591 
 
 
                            
 
                      Fig.14: Calibration curve of paclitaxel  in pH 7.4 at 220nm 
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7.4  Optimization: 
        Table 19 : Micrometric properties of optimized paclitaxel Nanoparticles                 
S No Parameters Report 
1 Tapped Density  0.563±0.04 (gm/ml) 
2 Bulk Density 0.584±0.01 (gm/ml) 
3 Carr's index 3.69±0.4 % 
4 Haunser's ratio 1.038±0.02 
 
Table 20: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-1 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative 
% drug 
release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative % 
drug release 
1 12.09 1 12.09 0 1.08 
2 20.73 1.41 20.73 0.30 1.31 
3 29.87 1.73 29.87 0.47 1.47 
4 38.04 2 38.04 0.60 1.58 
5 45.22 2.23 45.22 0.69 1.65 
6 50.53 2.44 50.53 0.77 1.70 
7 56.00 2.64 56 0.84 1.74 
8 59.36 2.82 59.36 0.90 1.77 
9 64.90 3 64.90 0.95 1.81 
10 69.24 3.16 69.24 1 1.84 
12 74.64 3.46 74.64 1.07 1.87 
24 98.50 4.89 98.50 1.38 1.99 
 
 
 
 
n =  3 
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Fig.15: Zero Order Release Plot for Formulation PXN-1 
 
 
Fig.16:  First order Release Plot for Formulation PXN-1 
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Fig.17:  Higuchi Release Plot for Formulation PXN-1 
 
 
Fig.18: Peppas Release Plot for Formulation PXN-1 
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Table 21: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-2 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative % 
drug release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative % 
drug 
 release 
1 9.69 1 9.69 0 0.98 
2 19.47 1.41 19.47 0.30 1.28 
3 28.26 1.73 28.26 0.47 1.45 
4 34.74 2 34.74 0.60 1.54 
5 41 2.23 41 0.69 1.61 
6 46.37 2.44 46.37 0.77 1.66 
7 50.17 2.64 50.17 0.84 1.70 
8 56.17 2.82 56.17 0.90 1.74 
9 61.04 3 61.04 0.95 1.78 
10 67.28 3.16 67.28 1 1.82 
12 72.87 3.46 72.87 1.07 1.86 
24 97.03 4.89 97.03 1.38 1.98 
    n =  3  
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Fig.19: Zero order Release Plot for Formulation PXN-2 
 
 
Fig.20: First order Release Plot for Formulation PXN-2 
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Fig.21: Higuchis Release Plot for Formulation PXN-2  
 
 
 
Fig.22: Peppas Release Plot for Formulation PXN-2  
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Table  22: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-3 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative % 
drug release 
Square root 
time 
Cumulative % 
drug release Log time 
Log 
cumulative % 
drug release 
1 8.12 1 8.12 0 0.90 
2 17.30 1.41 17.30 0.30 1.23 
3 26.27 1.73 26.27 0.47 1.41 
4 33.13 2 33.13 0.60 1.52 
5 39.01 2.23 39.01 0.69 1.59 
6 43.85 2.44 43.85 0.77 1.64 
7 48.89 2.64 48.89 0.84 1.68 
8 54.31 2.82 54.31 0.90 1.73 
9 58.06 3 58.06 0.95 1.76 
10 64.75 3.16 64.75 1 1.81 
12 69.24 3.46 69.24 1.07 1.84 
24 95.25 4.89 95.25 1.38 1.97 
    n =  3  
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Fig .23: Zero Order Release Plot for Formulationpaclitaxel-3 
 
 
Fig.24:  First order Release Plot for Formulation PXN-3  
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Fig.25: Higuchis Release Plot for Formulation PXN-3  
 
Fig.26: Peppas Release Plot for Formulation PXN-3  
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Table 23: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-4 
In vitro drug release data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative % 
drug release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative % 
drug release 
1 8.52 1 8.52 0 0.93 
2 18.68 1.41 18.68 0.30 1.27 
3 26.25 1.73 26.25 0.47 1.4 
4 33.50 2 33.50 0.60 1.52 
5 39.06 2.23 39.06 0.69 1.59 
6 43.81 2.44 43.81 0.77 1.64 
7 48.45 2.64 48.45 0.84 1.68 
8 54.14 2.82 54.14 0.90 1.73 
9 59.9 3 59.97 0.95 1.77 
10 63.24 3.162 63.24 1 1.80 
12 69.17 3.46 69.17 1.07 1.83 
24 97.47 4.89 97.47 1.38 1.98 
    n =  3  
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Fig.27: Zero Order Release Plot for Formulation paclitaxel-4 Nanoparticles 
 
 
Fig.28: First order Release Plot for Formulation PXN-4 
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Fig.29: Higuchis Release Plot for Formulation paclitaxel-4 Nanoparticles 
 
 
 
Fig .30: Peppas Release Plot for Formulation PXN-4 
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Table 24: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-5 
In vitro drug release data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative % 
drug release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative 
% drug 
release 
1 6.79 1 6.79 0 0.83 
2 16.76 1.41 16.76 0.30 1.22 
3 24.57 1.73 24.57 0.47 1.39 
4 31.22 2 31.22 0.60 1.49 
5 37.02 2.23 37.02 0.69 1.56 
6 42.24 2.44 42.24 0.77 1.62 
7 46.78 2.64 46.78 0.84 1.67 
8 52.33 2.82 52.33 0.90 1.71 
9 57.87 3 57.87 0.95 1.76 
10 61.34 3.16 61.34 1 1.78 
12 67.10 3.46 67.10 1.07 1.82 
24 94.60 4.89 94.60 1.38 1.97 
 
   n =  3  
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Fig. 31: Zero Order Release Plot for Formulation PXN-5 
 
 
 
 
 
Fig. 32: First order Release Plot for Formulation PXN-5  
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Fig.33: Higuchis Release Plot for Formulation PXN-5 
 
 
 
Fig .34: Peppas Release Plot for Formulation PXN-5 
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Table 25: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-6 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative 
% drug 
release 
Square root 
time 
Cumulative % 
drug release Log time 
Log 
cumulative % 
drug release 
1 4.90 1 4.90 0 0.69 
2 12.98 1.41 12.98 0.30 1.11 
3 20.80 1.73 20.80 0.47 1.31 
4 25.84 2 25.84 0.60 1.41 
5 30.74 2.23 30.74 0.69 1.48 
6 34.82 2.44 34.82 0.77 1.54 
7 40.59 2.64 40.59 0.84 1.60 
8 45.02 2.82 45.02 0.90 1.65 
9 51.92 3 51.92 0.95 1.71 
10 57.96 3.16 57.96 1 1.76 
12 63.68 3.46 63.68 1.07 1.80 
24 92.85 4.89 92.85 1.38 1.96 
    n =  3  
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Fig.35:Zero order Release Plot for Formulation PXN-6  
 
 
 
Fig. 36: First order Release Plot for Formulation PXN-6  
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Fig .37: Higuchis Release Plot for Formulation PXN-6 
 
 
Fig.38: Peppas Release Plot for Formulation PXN-6 
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Table 26: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-7 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative 
% drug 
release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative % 
drug release 
1 12.09 1 12.15 0 1.08 
2 21.73 1.46 21.69 0.35 1.31 
3 24.85 1.78 29.80 0.49 1.47 
4 32.02 2 36.07 0.64 1.58 
5 42.20 2.28 45.22 0.66 1.65 
6 51.51 2.46 52.53 0.75 1.75 
7 53.00 2.68 56 0.87 1.74 
8 56.32 2.72 59.36 0.93 1.77 
9 64.89 3 64.90 0.94 1.82 
10 68.27 3.20 69.24 1 1.86 
12 76.70 3.32 74.64 1.09 1.82 
24 88.00 4.85 99.00 1.36 1.94 
    n =  3  
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Fig.15: Zero Order Release Plot for Formulation PXN-7 
 
 
Fig.16:  First order Release Plot for Formulation PXN-7 
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Fig.17:  Higuchi Release Plot for Formulation PXN-7 
 
 
Fig.18: Peppas Release Plot for Formulation PXN-7 
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Table 27: Invitro Release Profile of  Paclitaxel Nanoparticle from Formulation PXN-8 
In vitro drug release 
data Higuchi’s data Peppa’s data 
Time 
(hrs) 
Cumulative % 
drug release 
Square root 
time 
Cumulative 
% drug 
release 
Log time 
Log 
cumulative % 
drug 
 release 
1 9.60 1 9.62 0 0.93 
2 15.40 1.44 19.40 0.30 1.24 
3 29.23 1.66 28.22 0.42 1.42 
4 32.69 2 32.70 0.62 1.53 
5 45 2.44 45 0.63 1.60 
6 45.30 2.45 42.32 0.72 1.63 
7 52.13 2.72 51.16 0.81 1.72 
8 53.15 2.80 56.18 0.93 1.70 
9 63.02 3 64.07 0.92 1.73 
10 64.38 3.12 63.22 1 1.80 
12 70.83 3.40 75.87 1.03 1.83 
24 97.00 4.80 99.03 1.32 1.93 
    n =  3  
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Fig.19: Zero order Release Plot for Formulation PXN-8 
 
 
 
Fig.20: First order Release Plot for Formulation PXN-8 
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Fig.21: Higuchis Release Plot for Formulation PXN-8 
 
 
 
Fig.22: Peppas Release Plot for Formulation PXN-8  
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Fig.39: Comparative Zero order Release Plot for Formulations  
PXN-1 to PXN-3 Nanoparticles 
 
 
Fig .40: Comparative Zero order Release Plot for Formulations 
 PXN-4 to PXN-8 Nanoparticles 
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   Table 28 :Release Profile of Paclitaxel NP From Formulation PXN-1 to PXN-8 
 
Time 
(hrs) 
Cumalative % Drug rlease 
PXN-1 PXN-2 PXN-3 PXN-4 PXN-5 PXN-6 PXN-7 PXN-8 
1 12.09 9.69 8.12 8.52 6.79 4.90 12.09 9.60 
2 20.73 19.47 17.30 18.68 16.76 12.98 21.73 15.40 
3 29.87 28.26 26.27 26.25 24.57 20.80 24.85 29.23 
4 38.04 34.74 33.13 33.50 31.22 25.84 32.02 32.69 
5 45.22 41 39.01 39.06 37.02 30.74 42.20 45 
6 50.53 46.37 43.85 43.81 42.24 34.82 51.51 45.30 
7 56.00 50.17 48.89 48.45 46.78 40.59 53.00 52.13 
8 59.36 56.17 54.31 54.14 52.33 45.02 56.32 53.15 
9 64.90 61.04 58.06 59.9 57.87 51.92 64.89 63.02 
10 69.24 67.28 64.75 63.24 61.34 57.96 68.27 64.38 
12 74.64 72.87 69.24 69.17 67.10 63.68 76.70 70.83 
24 98.50 97.03 95.25 97.47 94.60 92.85 88.00 97.00 
    
 
  n =  3  
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Fig. 41: Comparative Zero order Release Plot for Formulations PXN-1to PXN-8 
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 Table 29: In-Vitro Release Kinetics of  Prepared Nanoparticles 
Formulation 
code 
Mathematical models (release kinetics) 
Zero order 
kinetics 
First order 
kinetics 
Higuchi’s Peppa’s 
r2 r2 r2 r2 N 
PXN -1 0.86 0.95 0.98 0.97 0.68 
PXN -2 0.88 0.97 0.98 0.97 0.73 
PXN -3 0.89 0.98 0.98 0.97 0.78 
PXN -4 0.91 0.94 0.99 0.97 0.76 
PXN -5 0.90 0.97 0.99 0.99 0.82 
PXN -6 0.93 0.97 0.99 0.97 0.91 
PXN -7 0.88 0.92 0.99 0.97 0.65 
PXN -8 0.90 0.96 0.99 0.97 0.72 
 
Table 30: Drug entrapment efficiency of  loaded Nanoparticles 
S.No Formulation 
code 
Quantity 
of AgNo3 
Theoretical 
drug 
loading 
(%) 
Actual 
drug 
loading 
±S.D 
Drug 
Entrapment 
Efficiency 
(%) 
Particle  
Size 
1 PXN-1 0.017gm 89.5 86.51 96.66 1.51µm 
2 PXN-2 0.17gm 46.8 44.9 96 1.26µm 
3  PXN-3 0.5gm 23.07 21.98 95.3 1.03µm 
4 PXN-4 0.8 gm 15.7 14.85 94.6 9.27nm 
5 PXN-5 1.0 gm 13.04 12.25 94 856nm 
6 PXN-6 1.17gm 11.36 10.59 93.3 717nm 
7 PXN-7 1.17gm 11.36 10.50 92.4 635nm 
8 PXN-8 1.17gm 11.36 10.20 89.78 935nm 
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7.6  Particle Size Analysis (PSA)(Optmized Formulation PXN-6) 
 
           Fig.42:Particle Size Analysis of paclitaxel silver nitrate nanoparticles 
 
 
Particle Size Report of  Silver Nanoparticle PXN 
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                           Particle Size Report of  Silver nanoparticle PXN 
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7.7  Zeta Potential Analysis 
S.No Sample Zeta Potential (mV) Stability behavior of sample 
1 Paclitaxel -57.3 Good stability 
 
 
          Fig.43:Zeta potential Analysis of Paclitaxel silver nitrate nanparticles. 
 
 
Zeta Potential Report of  Silver nanoparticle of paclitaxel 
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7.8 SEM Analysis: 
Fig.44: SEM images of  Loaded Nanoparticles for best formulation PXN- 6 
 
 
(a- M 10,000) 
 
(b M- 15,000) 
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(c  M-20,000) 
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7.9 Acceleratd stability study: 
 
Table 31 : Stability testing parameters for optimized Paclitaxel silver nitrate                                              
                   Nannoparticles 
Parameter 
Storate condition 40°C ± 2°C & 75% ± 5% RH 
Initial 1st Month 2nd Month 
Appearance Light yellow Light yellow Light yellow 
Average weight (mg) 350mg 350mg 350mg 
Drug content(%) 99.1 99.0 98.54 
 
Table 32 : In-vitro dissolution study of Nanocapsule 
Dissolution Time 
(hr) 
Storate condition 40°C ± 2°C & 75% ± 5% RH 
Initial 1st Month 2nd Month 
1 27.69 27.94 29.98 
2 35.53 36.86 38.014 
3 45.23 48.12 50.46 
4 55.84 59.01 60.69 
5 66.92 67.13 69.14 
6 74.76 78.45 79.69 
7 83.53 89.16 90.45 
8 94.61 95.63 96.12 
9 96.51 96.53 96.55 
10 97.61 97.63 97.70 
12 97.81 97.85 97.88 
24 98.61 98.63 98.67 
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        Fig.45: Comparative dissolution profile of Paclitaxel silver nitrate                  
                       Nannoparticles (stability study) 
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Discussion 
 
8.1.1 Selection of Drug and Excipients: 
Formulation development started from selection of API, the cost efficiency, 
easy availability and challenging aspects of drug properties made to select Paclitaxel. 
Then the excipients were selected based on the previous studies and compatibility. 
8.1.2 Selection of Method: 
 Preparation of Nanoparticles started from the selection of suitable methodto 
prepare Nanoparticles. The Silver nitrate and Trisodium citrate was selected and 
individual Nanoparticles were prepared and evaluated. Silver nitrate and trisodium 
citrate were used as starting materials for the preparation of Paclitaxel silver nitrate 
Nanoparticles. The silver colloid was prepared by using chemical Precipitation 
method. This was achieved after a many trail batch. Finally the formulation of 
Paclitaxel Nanoparticle was finalized. 
8.2 Raw material analysis of Paclitaxel:  
8.2.1 Description and solubility: 
The description of the Active Pharmaceutical Ingredient of Paclitaxelwas 
found to be complies with USP. Solubility of the Paclitaxel was found with different 
solvents. The results were shown in Table17 and it was freely soluble in Methanol, 
Dichloromethane, Ethanol, Slightly soluble in Octanol, Ethylacetate and poorly 
soluble in Water. 
8.2.2 Identification test: 
         The test Absorption time ,Melting point, Retention time and assay was done to 
identify the Paclitaxel .The results were shown in Table 13& 14 that all parameters 
were complies with USP.The percentage purity of Paclitaxel was not less than 97.0% 
and not more than 102.0% calculated on the anhydrous , solvent-free basis. 
8.3 Incompatibility study: 
8.3.1  Fourier Transformer Infrared spectroscopy (FT-IR): 
The development of a successful formulation depends only on a suitable 
selection of excipients. Hence the physical state of the drug paclitaxel, silver nitrate 
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and the combination of drug and polymers used for Nanoparticles preparation were 
studied by FTIR (Fourier transform infrared spectroscopy) to know the drug – 
polymer compatibility.The physicochemical compatibility of the drugs and the 
polymer was obtained by FTIR studies. The interpretation values of the FTIR were 
mentioned in the Table 17.Therefore, there was no alteration and no interaction was 
observed between polymer and drug in combination. All the characteristic peaks of, 
were present in combination, thus indicating no compatibility between drug and 
polymers and finally confirm that there was no chemical modification of drug have 
been taken place.Thus, from IR spectra studies we can draw a conclusionthat the drug 
remains in its normal form without undergoing any interaction with the polymers. 
8.4 Evaluation of Paclitaxel Nanoparticles: 
8.4.1  Nanoparticles size determination: 
The particle size of the prepared Nanoparticles was determined by particle size 
analyzer (Beckman Coulter) and it was shown in Fig. 42. The Average particle size of 
the loaded Nanoparticles were found to be 717.4 ± nm. All the, prepared formulations 
were found to be in the nano range. 
8.5 Pre-formulation Evaluation: 
The angle of repose for the formulation was determined and was found to be 
within the limit .The formulation PXN-6 had excellent flow and other formulation 
showed good flow. 
The bulk density of all formulations was found to be in the limit of 0.4 to 0.6 
hence it was within the limit. 
The Carr’s index and Hansuer’s ratio were found to be within the limit the 
results were shown in Table20.  
8.6  Drug release kinetics: 
The mechanism of drug release can be predicted by ‘n’ value: 
 If ‘n’ values which is less than 0.45, the drug release mechanism would be 
Fickian diffusion mechanism. 
 If ‘n’ value is more than 0.45 and less than 1, the release mechanism would be 
non- Fickian diffusion. 
 If ‘n’ value is equal to 1, the drug release mechanism would be case II 
transport (Zero order release). 
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 If ‘n’ value is more than 1, the release mechanism would be super case II 
transport. 
All the prepared formulations are having diffusion exponent value (n) more 
than 0.45 and less than 1, this indicates that the release mechanism follows non – 
Fickiandiffusion. The release kinetic graphs for best formulations are shown in Fig.39 
to 41.The linear regression analysis of Nanoparticles shown as R2 values in Table 29. 
When the data were plotted according to the zero-order equation, for all formulations 
(PXN-1 to PXN-6) showed a fairly linear, with regression (R2) values between (0.869 
to 0.935) clearly indicate that the drug wasn't released as per zero order mechanism. 
All the formulation expressed by first-order plots shows linearity with regression 
coefficient (R2) value as (0.953 to 0.981) also not close to infinity indicate the drug 
release process is not as per First-order plot. The Higuchis plots of all formulations 
were found to be highly linear, and close to infinity as indicated by their high 
regression (R2) values as (0.98 to 0.993). Therefore, it was ascertained that the drug 
permeation from these formulations could follow either near Higuchis or Higuchis 
order kinetics. Hence the release mechanism was shifted from the zero order to first 
order, followed by Higuchis release kinetics. 
Further, to understand the drug release mechanism, the data were fitted to 
Pappas equation. In the present study also it was observed Table 27 that no value was 
obtained between (0.686 to 0.918) for all formulations. These values, suggesting that 
more than one mechanism may be involved in release kinetics. 
8.7  Entrapment Efficiency:  
 As seen from drug loading, Encapsulation Efficiency of Paclitaxel NP was 
high (above 90%) for formulation prepared with TSC. However, it increased from 
89.78% to 96.66% with use of TSC as shown in Table 4. This could be due to the fact 
that  is due to the high  solubility of  drug in solvent resulting in high concentrations 
of the drug present in the preparation medium in the precipitation method.  
8.8      Invitro dissolution study 
  In vitro drug release from the Paclitaxel NP in phosphate buffer pH 7.4 was 
performed using dialysis bag diffusion technique. The in vitro drug release profile of 
Paclitaxel NP formulations obtained from dialysis experiment is shown in Fig.10 No 
burst release of paclitaxel NP was observed from these any of the eight formulations 
but formulation PXN-1 and PXN-8  gave 12 % of the initial drug release might be due 
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to lower silver nitrate concentration (0.001M) and lower concentration of TSC(3 ml), 
increases drug release slightly. Paclitaxel is a hydrophobic drug and thus it is expected 
that it will remain in hydrophobic domains of the precipitate. Entire drug release 
profile of paclitaxel was seemed to be diffusion-controlled as reported.67 
 It was observed that the drug release from the formulations slightly decreases 
as the particle size of the formulation decreases and all the eight formulations showed 
a continuous drug release from first hour. But upon increasing the concentration TSC 
cross linking agent by double, release was found to be decreases from beginning. This 
could be viewed as reduction of silver by citrate concentration yielded more 
hydrophobic surface which retard drug release. The drug release found to be 
dependent on the concentration of both silver nitrate and TSC material employed. 
Nanoparticles prepared with high concentration of Silver nitrate showed only 88% 
(PXN -8)  of drug release at 24 hour. When silver nitrate concentration   was at low 
(PXN 1-PXN6), release was almost by 90% at 24 hour. Release mechanism model 
was chosen, based on goodness of fit test. Based on the highest regression values (r), 
the best of fit model for all six formulations was Higuchi Model. Peppa’s model with 
n ~ 0.5 value indicating non-fickian diffusion release. Thus showing release of PXN-6 
was found to follow Higuchi’s classical diffusion model and diffusion was non-
Fickian 
8.9  Optimization: 
 The effect of Trisodium citrate (TSC- cross-linking agents) on the 
characteristics of the Paclitaxel Nanoparticle (NP) prepared was studied. The 
Paclitaxel NP were characterized for entrapment efficiency, particle size, in-vitro drug 
release, and surface morphology. The TSC cross-linked Paclitaxel NP was white in 
color and was obtained as a fine powder. As shown in Table 9, the TSC volume used 
for cross-linking does have influence on the entrapment efficiency and the particle 
size of the Paclitaxel NP. The Paclitaxel NP cross-linked using TSC shows high 
entrapment efficiency of around 96.6%. The average mean diameters of the TSC cross 
–linked Paclitaxel NP ranged from 1.51 ȝm to 635 nm. 
As shown in Figure 45, an increase in the concentration of TSC led to a decrease in 
the rate of drug release. Paclitaxel NP prepared using 3.0 ml of TSC releases the drug 
slowly compared to the Paclitaxel NP in which 10 ml of TSC was used. However, a 
burst effect was not observed in any of  the formulations. In general, around 50% of 
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the drug is released in the 7-8 hour, followed by slower release for a period of 24 h. 
From fourth hour, the drug release was controlled manner for a period of 12 h. There 
is a difference in the drug release rates of the all formulations. The scanning electron 
microscopy study reveals that the surface of the microspheres is rough which may be 
because of the drug present on the surface.Based on particle size, Entrapment 
efficiency and release rate, Formulation PXN-6 was optimized for Further study. 
8.9.1  Zeta Potential: 
 Measurements of zeta potential were also carried out in order to study the 
stability of nanoparticles as this extremely important for many applications, Surface 
zeta potentials were measured using the zeta analyzer (Beckman Coulter Delsa Nano 
C, Brea, USA) Liquid samples of the nanoparticles (5ml) were diluted with double 
distilled water (30 mL) and the pH was then adjusted to the required value. The 
samples were shaken for 30 minutes. After shaking the zeta potential of the metallic 
particles was measured. A zeta potential was used to determine the surface potential 
of the silver nanoparticles. In each method, an average of two separate measurements 
was reported. Table 31 is summarizing the zeta potential measurements of samples in 
a solution form. For synthesis nanoparticles using different methods, zeta values were 
measured and found to be – 57.3 mV at pH=7. The value of the zeta potential of 
Silver NPs provides satisfactory evidence about their little tendency towards 
aggregation when its negative charges with a diameter of 717.6 nm. This behavior 
unambiguously suggests the presence of strong electric charges on the particle 
surfaces to hinder agglomeration. These values were found to fall in the negative side 
which showed the efficiency of the capping materials in stabilizing the nanoparticles 
by providing intensive negative charges that keep all the particles away from each 
other. This result suggests that the Silver NPs particles and thus their solution is stable 
behavior a shown in Fig. 43.   
 . 
8.9.2  Scanning Electron Microscopy 
SEM analysis was performed on the prepared loaded Nanoparticles to access 
their surface morphological characteristics  of prepared Silver NPs using Tri sodium 
citrate a)Low, Medium  and b) high magnifications as shown in Fig. 44 (a.b.c).   
 SEM was performed for best formulations to assess their surface. The 
polymer surface of the Nanoparticles appeared spherical with smooth texture surface. 
Discrete nature, and distinct particle size and shape with a smooth surface. 
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The morphology particles were measured. The silver Nanoparticles in the 
citrate cross linked were in a spherical form with a well defined particle size. The 
particle size strongly depend preparation conditions. The average particle size of the 
measured particles was as small as 645 nm to 1.12 µm.  
8.9.3 Stability study: 
The colour and shape of Paclitaxel were found to be unchanged even at the 
end of 2nd month stability study in all conditions. The results were shown in Table 32 
to 33&Fig45.In order to perform the stability study the Nanoparticles were placed 
with blister packing material and folded in to the strips, then placed into stability 
chamber .At the end of the month one set of the colloidal Nanoparticle were analyzed 
for shape average weight and drug content. There was no change in the colour and 
shape of Nanoparticles .Also no changed absorved in release behavior up to two 
months when compared to optimized formulation. Sufficient precautionary measures 
were taken to prevent the photolytic degradation of Paclitaxel. 
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Summary 
 
Drug delivery systems to the colon are being actively investigated in order to develop 
oral preparations of peptides and treat local colonic diseases, e.g., irritable bowel 
syndrome, ulcerative colitis, cancer, and infection.Paclitaxel is a microtubule-
stabilizing agent which promotes polymerization of tubululin causing cell death by 
disrupting the dynamics necessary for cell division. It has neoplastic activity 
especially against primary epithelial ovarian carcinoma, breast, colon, and non-small 
cell lung cancers. 
From the present investigation, the obtained results were summarized as follows; 
 The IR spectrum of pure drug and drug mixture indicated that there was no 
interaction between polymers and drug. 
 The Nanoparticles prepared were small, spherical with smooth surface having 
better yield and uniform encapsulation efficiency. 
 Paclitaxel nanoparticles were having an average particle size of 717.4 ± nm. 
  The Zeta Potential analysis showed the stability of colloidal dispersions of 
Nanosparticles. The Paclitaxel Nanoparticles showed with excellent stability 
of  
 -57.3mv 
 The shape of Nanoparticles was almost spherical and smooth as indicated by 
SEM. 
 Encapsulation efficiency for Paclitaxel nanoparticles was in the range of 
73.89% to 95.9% as the polymer concentration increases, the encapsulation 
efficiency also increases 
 Paclitaxel release from Nanoparticles was slow and extended period of time 
due to increase in polymer concentration. The release mechanisms for all the 
formulations followed by non-fickian diffusion mechanism. 
 The drug release from formulation PXN6 was 92.85% for a long period of 
24hrs. The release mechanisms for all the formulations followed by non-
fickian diffusion mechanism. 
Hence Nanoparticles prepared by precipitation method using silver nitrate 
showed promising results in delivering the drug, and there exist a scope for in-
vivo evaluation using suitable animal models. 
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Conclusion 
 The present in vitro study revealed that the Paclitaxel NP can be a useful means 
for the colon targeted delivery of drugs. Around 60% of the drug to be released at colon 
after regular transit (GIT) of  4-6  hour.  This work suggests the  Paclitaxel NP of the size 
ranging from 635 nm -717 nm and their solutions are stable at neutral  pH. The prepared 
Nanoparticle found to be stable without any tendency of aggregation and shown higher 
entrapment efficiency. The hydrophobic surface of the drug with silver release the drug 
slowly but up to 24 hours only. Because of higher in size of prepared Nanoparticle, 
release couldnot be prolonged for more than  24 hours: this finding is considered as 
drawback. The dissolution data indicates that the release of Paclitaxel NP with controlled 
manner is directly proportional with the size and concentration of Silver nitrate and 
crosslinking agent. Therefore, nanoparticles  release increased with smaller size of 
particles. In this study, the prepared paclitaxel NP exhibited prolonged intestinal 
absorption, and prevent gastric release, avoid gastric erosion side effects and thus 
improve patient compliance. Short term stability study reveal formulation in Capsule 
dosage form found to be stable without any major problem. However, further studies 
are needed to investigate these formulations to prepare Nanoparticles with desired 
size range of around 200 nm.  
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